0001847903-24-000046.txt : 20240326 0001847903-24-000046.hdr.sgml : 20240326 20240326161629 ACCESSION NUMBER: 0001847903-24-000046 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240325 FILED AS OF DATE: 20240326 DATE AS OF CHANGE: 20240326 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Anderson Karen M. CENTRAL INDEX KEY: 0001762176 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40445 FILM NUMBER: 24783740 MAIL ADDRESS: STREET 1: C/O CENTESSA PHARMACEUTICALS PLC STREET 2: 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM CITY: CHESHIRE STATE: X0 ZIP: WA14 2DT ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Centessa Pharmaceuticals plc CENTRAL INDEX KEY: 0001847903 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3RD FLOOR STREET 2: 1 ASHLEY ROAD CITY: ALTRINCHAM, CHESHIRE STATE: X0 ZIP: WA14 2DT BUSINESS PHONE: 44 7391 789784 MAIL ADDRESS: STREET 1: 3RD FLOOR STREET 2: 1 ASHLEY ROAD CITY: ALTRINCHAM, CHESHIRE STATE: X0 ZIP: WA14 2DT FORMER COMPANY: FORMER CONFORMED NAME: Centessa Pharmaceuticals Ltd DATE OF NAME CHANGE: 20210224 4 1 wk-form4_1711484173.xml FORM 4 X0508 4 2024-03-25 0 0001847903 Centessa Pharmaceuticals plc CNTA 0001762176 Anderson Karen M. C/O CENTESSA PHARMACEUTICALS PLC 3RD FL., 1 ASHLEY RD, ALTRINCHAM CHESHIRE X0 WA14 2DT UNITED KINGDOM 0 1 0 0 Chief People Officer 1 Ordinary Shares 2024-03-25 4 M 0 25010 4.01 A 102695 D Ordinary Shares 2024-03-25 4 M 0 19990 3.85 A 122685 D Ordinary Shares 2024-03-25 4 S 0 29995 11.6561 D 92690 D Ordinary Shares 2024-03-25 4 S 0 21165 12.2058 D 71525 D Share Option (right to buy) 4.01 2024-03-25 4 M 0 25010 0 D 2032-12-01 Ordinary Shares 25010 274990 D Share Option (right to buy) 3.85 2024-03-25 4 M 0 19990 0 D 2033-02-01 Ordinary Shares 19990 60010 D The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 23, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.07 to $12.035, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.07 to $12.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. 25% of the shares subject to such option shall vest and become exercisable on December 1, 2023 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter. 1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2023. /s/ Gregory Weinhoff, attorney-in-fact 2024-03-26